AR059985A1 - Tetrahidro-pirimidoazepinas como moduladores de trpv1 - Google Patents

Tetrahidro-pirimidoazepinas como moduladores de trpv1

Info

Publication number
AR059985A1
AR059985A1 ARP070101128A ARP070101128A AR059985A1 AR 059985 A1 AR059985 A1 AR 059985A1 AR P070101128 A ARP070101128 A AR P070101128A AR P070101128 A ARP070101128 A AR P070101128A AR 059985 A1 AR059985 A1 AR 059985A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
independently
halo
saturated monocyclic
Prior art date
Application number
ARP070101128A
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of AR059985A1 publication Critical patent/AR059985A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)

Abstract

Dichos compuestos pueden ser usados en composiciones farmacéuticas y para tratar trastornos y afecciones médicas intermediadas por TRPV1 Por lo tanto, los compuestos pueden ser administrados por ejemplo en dolor, prurito, tos, asma y enfermedad inflamatoria del intestino. Reivindicacion 1: Un compuesto de formula (1): donde: R1 es -H; NRaRb; un grupo -alquilo C1-6, -alquiloO C1-6, -S-alquilo C1-6, o -SO2-alquilo C1-6 no sustituido o sustituido con un sustituyente -OH, -Oalquilo C1-4, - NReRf, o halo sustituido; o un grupo cicloalquilo monocíclico no sustituido o sustituido con un -alquilo C1-6, -OH, -Oalquilo C1-4, -NReRf, o halo; donde Ra y Rb cada uno independientemente es -H; -alquilo C1-6, un grupo -alquilo C2-3 sustituido con -OH, -Oalquilo C1-4, -NRcRd, o halo sustituido; o un cicloalquilo monocíclico saturado, -alquilo C1-(cicloalquilo monocíclico saturado), heterocicloalquilo monocíclico saturado, -alquilo C1-(heterocicloalquilo monocíclico saturado), fenilo, o un grupo bencilo no sustituido o sustituido con uno, dos o tres porciones independientemente seleccionadas del grupo que consiste en -alquilo C1-6, OH, -Oalquilo C1-4, -NRpRq, y halo sustituidos, o Ra y Rb tomados conjuntamente con su nitrogeno de union forman un grupo heterocicloalquilo monocíclico saturado no sustituido o sustituido con uno, dos o tres porciones independientemente seleccionadas del grupo que consiste en -alquilo C1-6, -OH, -Oalquilo C1-4, -NRpRq, halo, -CO2H, y sustituyentes bencilo; donde Rc y Rd son cada uno independientemente -H o -alquilo C1-6, o Rc y Rd tomados conjuntamente con su nitrogeno de union forman un heterocicloalquilo monocíclico saturado; donde Rp y Rq son cada uno independientemente -H o -alquilo C1-6 o Rp y Rq tomados conjuntamente con su nitrogeno de union forman un heterocicloalquilo monocíclico saturado; donde Re y Rf son cada uno independientemente -H o -alquilo C1-6, o Re y Rf tomados conjuntamente con su nitrogeno de union forman un heterocicloalquilo monocíclico saturado; R2 es -H o -alquilo C1-6, R3 es un grupo fenilo, bencilo, fenetilo, indanilo, tiazolilo, tiofenilo, piridilo, pirimidinilo, pirazinilo, piridazinilo, quinolinilo, o isoquinolinilo no sustituido o sustituido con uno, dos, o tres sustituyentes Rg; donde cada sustituyente Rg es -alquilo C1-6, -OH, -Oalquilo C1-6, fenoxi, -CN, -NO2, N(Rh)Ri, -C(O)N(Rh)Ri, -N(Rh)C(O)Ri, -N(Rh)SO2 alquilo C1-6, -C(O)alquilo C1-6, -S(O)0-2-alquilo C1-6, -SO2CF3, SO2N(Rh)Ri, -SCF3, halo, -CF3, -OCF3, -COOH, C(O)Oalquilo C1-6, -C(Rj)2-CN, o -C(Rj)2-OH; o dos sustituyentes Rg adyacentes tomados conjuntamente forman -Oalquilo C1-2O-; donde Rh y Ri son cada uno independientemente -H o -alquilo C1-6; donde cada Rj es independientemente -H o -alquilo C1-6; y Ar es un grupo fenilo, piridilo, imidazolilo, pirimidinilo, piridazinilo, o un grupo heteroarilo fusionado-bicíclico no sustituido o sustituido con uno, dos o tres sustituyentes Rk; donde cada sustituyente Rk es independientemente -alquilo C1-6, -OH, -Oalquilo C1-6, fenoxi, -CN, -NO2, N(Rl)Rm, -C(O)N(Rl)Rm, N(Rl)C(O)Rm, -N(Rl)SO2 alquilo C1-6, -N(Rl)SO2CF3, -C(O)alquilo C1-6, -S(O)0-2-alquilo C1-6, -SO2CF3, SO2N(Rl)Rm, -SCF3, halo, -CF3, - OCF3, -COOH, o -C(O)Oalquilo C1-6; o dos sustituyentes Rk adyacentes tomados conjuntamente forman -Oalquilo C1-2O-; donde Rl y Rm son cada uno independientemente -H, -alquilo C1-6, o -CF3; o una sal farmacéuticamente aceptable, un profármaco farmacéuticamente aceptable o un metabolito de dicho compuesto farmacéuticamente activo.
ARP070101128A 2006-03-21 2007-03-20 Tetrahidro-pirimidoazepinas como moduladores de trpv1 AR059985A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78541506P 2006-03-21 2006-03-21

Publications (1)

Publication Number Publication Date
AR059985A1 true AR059985A1 (es) 2008-05-14

Family

ID=38353855

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101128A AR059985A1 (es) 2006-03-21 2007-03-20 Tetrahidro-pirimidoazepinas como moduladores de trpv1

Country Status (31)

Country Link
US (3) US8673895B2 (es)
EP (1) EP2024368B1 (es)
JP (1) JP5232768B2 (es)
KR (1) KR101461376B1 (es)
CN (1) CN101448835B (es)
AR (1) AR059985A1 (es)
AU (1) AU2007227203B2 (es)
BR (1) BRPI0709034B1 (es)
CA (1) CA2646977C (es)
CR (1) CR10387A (es)
DK (1) DK2024368T3 (es)
EA (1) EA017069B1 (es)
EC (1) ECSP088807A (es)
ES (1) ES2474152T3 (es)
HK (1) HK1129888A1 (es)
HR (1) HRP20140664T1 (es)
MX (1) MX2008012163A (es)
NI (1) NI200800253A (es)
NO (1) NO341676B1 (es)
NZ (1) NZ571343A (es)
PE (1) PE20080145A1 (es)
PL (1) PL2024368T3 (es)
PT (1) PT2024368E (es)
RS (1) RS53436B (es)
SG (1) SG177176A1 (es)
SI (1) SI2024368T1 (es)
TW (1) TWI440639B (es)
UA (1) UA92636C2 (es)
UY (1) UY30229A1 (es)
WO (1) WO2007109355A2 (es)
ZA (1) ZA200808975B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69638073D1 (de) * 1996-09-04 2009-12-24 Intertrust Tech Corp Zuverlässige Infrastrukturhilfssysteme, Verfahren und Techniken für sicheren elektronischen Handel, elektronische Transaktionen, Handelsablaufsteuerung und Automatisierung, verteilte Verarbeitung und Rechteverwaltung
US20080153845A1 (en) * 2006-10-27 2008-06-26 Redpoint Bio Corporation Trpv1 antagonists and uses thereof
CN101652367A (zh) * 2007-03-23 2010-02-17 辉瑞有限公司 作为5-ht2c激动剂的嘧啶并[4,5-d]氮杂卓衍生物
WO2009078999A1 (en) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
US20090156598A1 (en) * 2007-12-17 2009-06-18 Lebsack Alec D Imidazolopyrimidine modulators of TRPV1
AU2009276339B2 (en) * 2008-07-31 2012-06-07 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
JP2012507512A (ja) * 2008-11-06 2012-03-29 アストラゼネカ・アクチエボラーグ アミロイドβのモジュレーター
EP2445346A4 (en) * 2009-06-24 2012-12-05 Genentech Inc OXOHETEROCYCLIC FUSIONED PYRIMIDINE COMPOUNDS AND COMPOSITIONS AND METHOD FOR THEIR USE
MX2012005463A (es) * 2009-11-12 2012-09-12 Hoffmann La Roche Compuestos de purina n/9 sustituida, composiciones y metodos de uso.
EP2499143B1 (en) * 2009-11-12 2016-03-16 F.Hoffmann-La Roche Ag N7-substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
DK2585216T3 (da) 2010-06-23 2020-02-03 Johnson Matthey Plc Pi-allylpalladium- og pi-allylnickel-komplekser til anvendelse som katalysatorer i carbon-carbon- og carbon-nitrogen-koblingsreaktioner
CN102154494B (zh) * 2011-03-14 2013-01-02 中国人民解放军军事医学科学院基础医学研究所 一种用于儿童哮喘检测的标志物
PL2958913T3 (pl) 2013-02-20 2019-03-29 Lg Chem, Ltd. Agoniści receptora sfingozyno-1-fosforanowego, sposoby ich przygotowania i zawierające je jako środek aktywny farmaceutyczne kompozycje
CN103641762A (zh) * 2013-12-18 2014-03-19 中国药科大学 一类trpv1/cox-2双重抑制剂、其制备方法及其制备镇痛药物的用途
EP4050010B1 (en) 2019-12-03 2023-10-18 LG Chem, Ltd. Sphingosine-1-phosphate receptor agonist, preparation method therefor, and pharmaceutical composition comprising same as active agent

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160834A (en) 1977-03-09 1979-07-10 Eli Lilly And Company 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas
JPH03167178A (ja) 1989-11-24 1991-07-19 Taiji Nakayama ピリミジン誘導体
JPH03255077A (ja) 1990-03-01 1991-11-13 Taiji Nakayama ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤
AU3427093A (en) 1992-01-15 1993-08-03 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JPH06172355A (ja) 1992-04-14 1994-06-21 Mect Corp ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤
JP3167178B2 (ja) 1992-05-28 2001-05-21 積水化学工業株式会社 庇構造および庇カバー受材
JPH0625243A (ja) 1992-07-08 1994-02-01 Sankyo Co Ltd １−メチルカルバペネム誘導体の製造法
DE19624069A1 (de) 1996-06-17 1997-12-18 Thomae Gmbh Dr K Benzazepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6150343A (en) 1993-06-30 2000-11-21 University Of Pittsburgh Camptothecin analogs and methods of preparation thereof
US5834461A (en) 1993-07-29 1998-11-10 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
AR002459A1 (es) 1995-01-17 1998-03-25 American Cyanamid Co Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion.
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
BR9611731A (pt) 1995-11-17 1999-02-23 Du Pont Composto mistura composição herbicida e método para controlar o crescimento de vegetação indesejada
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
AU2980797A (en) 1996-06-11 1998-01-07 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and medicinal uses thereof
WO1997047624A1 (en) 1996-06-13 1997-12-18 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP2001514631A (ja) 1997-03-07 2001-09-11 ノボ ノルディスク アクティーゼルスカブ ４，５，６，７−テトラヒドロ−チエノ［３，２−ｃ］ピリジン誘導体類、それらの製造方法及び使用
ZA982368B (en) 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
JP3255077B2 (ja) 1997-04-23 2002-02-12 日本電気株式会社 電話機
EP1001970B1 (en) 1997-06-25 2007-03-07 Pfizer Inc. Dipeptide derivatives as growth hormone secretagogues
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6358951B1 (en) 1998-08-21 2002-03-19 Pfizer Inc. Growth hormone secretagogues
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
JP2001097979A (ja) 1999-07-28 2001-04-10 Takeda Chem Ind Ltd 縮合複素環化合物、その製造法および用途
US7160890B2 (en) 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
JP2001294572A (ja) 2000-02-09 2001-10-23 Dai Ichi Seiyaku Co Ltd 新規スルホニル誘導体
EP1149583A3 (en) 2000-04-13 2001-11-14 Pfizer Products Inc. Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues
DOP2001000154A (es) 2000-05-25 2002-05-15 Pfizer Prod Inc Combinación de secretagogos de hormona del crecimiento y antidepresivos
ES2333097T3 (es) 2000-05-31 2010-02-17 Raqualia Pharma Inc Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
IL143690A0 (en) 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL152781A0 (en) 2000-06-28 2003-06-24 Pfizer Prod Inc Melanocortin receptor ligands
IL143942A0 (en) 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
EP1181933A3 (en) 2000-06-29 2002-04-10 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating or increasing appetite
MXPA02012560A (es) 2000-06-30 2003-05-14 Elan Pharm Inc Compuestos para tratar la enfermedad de alzheimer.
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US6369222B1 (en) 2000-07-18 2002-04-09 Hoffmann-La Roche Inc. mGluR antagonists and a method for their synthesis
AUPQ887100A0 (en) * 2000-07-19 2000-08-10 Dynamic Digital Depth Research Pty Ltd Image processing and encoding techniques
IL144468A0 (en) 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
ATE326458T1 (de) 2000-09-15 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1192943A3 (en) 2000-09-28 2002-11-27 Pfizer Products Inc. Use of growth hormone secretagogues in conjunction with physical exercise
NZ525324A (en) 2000-10-20 2005-03-24 Eisai Co Ltd Nitrogenous aromatic ring compounds
DK1353916T3 (da) 2000-12-21 2007-01-29 Vertex Pharma Pyrazolforbindelser der er egnede som proteinkinaseinhibitorer
WO2002051813A2 (en) 2000-12-27 2002-07-04 Merck Patent Gmbh PROCESS FOR THE PREPARATION OF α-AMINOSUBSTITUTED CARBOXYLIC ACID AMIDES
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
US7105667B2 (en) * 2001-05-01 2006-09-12 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
EP2336133A1 (en) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
MXPA04005209A (es) 2001-11-30 2004-08-19 Schering Corp Antagonistas del receptor de adenosina a2a.
RS63204A (en) 2002-01-17 2006-10-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
JP2003321472A (ja) 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
US20030199514A1 (en) 2002-03-27 2003-10-23 Fryburg David A. Methods for improving efficacy of treatment with growth hormone secretagogues
US7524852B2 (en) 2002-06-07 2009-04-28 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
US7384937B2 (en) * 2002-11-06 2008-06-10 Bristol-Myers Squibb Co. Fused heterocyclic compounds and use thereof
JP2006517234A (ja) 2003-02-10 2006-07-20 アムジエン・インコーポレーテツド バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用
AR045979A1 (es) 2003-04-28 2005-11-23 Astrazeneca Ab Amidas heterociclicas
WO2004108120A1 (en) 2003-06-11 2004-12-16 Pfizer Products Inc. Use of growth hormone secretagogues for treatment of fibromyalgia
BRPI0412712A (pt) 2003-07-21 2006-09-26 Pfizer Prod Inc compostos azapolicìclicos fundidos com heteroarila
PE20050355A1 (es) 2003-08-05 2005-05-16 Vertex Pharma Composiciones referidas a inhibidores de canales ionicos regulados por voltaje
EP1655286A4 (en) 2003-08-08 2007-09-05 Sumitomo Chemical Co PROCESS FOR PRODUCING A LOW-FUSION CRYSTAL OF A FREE DISOPYRAMIDE BASE
AU2004270740A1 (en) 2003-09-09 2005-03-17 Neurogen Corporation 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
AU2004278382B2 (en) 2003-09-30 2008-09-18 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005033115A1 (en) 2003-10-07 2005-04-14 Astrazeneca Ab New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
US7816356B2 (en) 2003-11-14 2010-10-19 Daniel Yohannes Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands
US20070135454A1 (en) 2003-11-14 2007-06-14 Tracy Bayliss Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1)
JP2005162673A (ja) 2003-12-03 2005-06-23 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体
TW200530235A (en) 2003-12-24 2005-09-16 Renovis Inc Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
US7312330B2 (en) 2003-12-24 2007-12-25 Renovis, Inc. Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
AU2005206562A1 (en) 2004-01-23 2005-08-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
WO2005082865A1 (ja) * 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
EP1731523A4 (en) 2004-04-01 2009-08-12 Takeda Pharmaceutical THIAZOLOPYRIMIDINE DERIVATIVE
GB0412467D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
ITMI20041231A1 (it) 2004-06-18 2004-09-18 Pharmeste Srl Antagonisti del recettore dei vanilloidi trpv1
US7617501B2 (en) 2004-07-09 2009-11-10 Quest Software, Inc. Apparatus, system, and method for managing policies on a computer having a foreign operating system
ITMI20041566A1 (it) 2004-07-30 2004-10-30 Indena Spa "trpv1 agonisti, formulazioni che li contengono e loro usi"
FR2874015B1 (fr) 2004-08-05 2006-09-15 Sanofi Synthelabo Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
JP2006083085A (ja) 2004-09-15 2006-03-30 Kyowa Hakko Kogyo Co Ltd 二環性ピリミジン誘導体の製造法およびその合成中間体
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US7459448B2 (en) 2004-10-04 2008-12-02 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2006044762A2 (en) * 2004-10-15 2006-04-27 Bayer Pharmaceuticals Corporation Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor
EP1844038A2 (en) 2004-11-24 2007-10-17 Abbott Laboratories Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor and uses thereof
US20060128710A1 (en) 2004-12-09 2006-06-15 Chih-Hung Lee Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
CA2594998A1 (en) 2005-01-25 2006-08-03 Neurogen Corporation Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues
WO2006123242A1 (en) 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
PE20070171A1 (es) 2005-06-30 2007-03-08 Boehringer Ingelheim Int GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa
US20070032473A1 (en) 2005-07-19 2007-02-08 Kai Gerlach Substituted amides and their use as medicaments
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
CN101277700B (zh) * 2005-08-04 2013-02-20 詹森药业有限公司 作为5-羟色胺受体调节剂的嘧啶化合物
WO2007047798A1 (en) 2005-10-21 2007-04-26 Sensis Corporation Method and apparatus for providing secure access control for protected information
EP1951244A4 (en) 2005-11-22 2010-08-25 Glaxosmithkline Llc CALCILYTIC COMPOUNDS
JP4678685B2 (ja) 2005-12-26 2011-04-27 株式会社吉野工業所 エアゾール式液噴出器
DE102005062987A1 (de) 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
JP2009523748A (ja) 2006-01-18 2009-06-25 シエナ ビオテク ソシエタ ペル アチオニ α７ニコチン性アセチルコリン受容体の調節物質およびそれらの治療への使用
EP1818330A1 (de) 2006-02-14 2007-08-15 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel
JP2009531314A (ja) 2006-03-10 2009-09-03 ニューロジェン・コーポレーション ピペラジニルオキソアルキルテトラヒドロイソキノリン類および関連類似物
MX2008012161A (es) 2006-03-21 2008-10-03 Schering Corp Compuestos heterociclicos de piridina sustituida con actividad antagonista de cxcr3.
JP5167250B2 (ja) 2006-05-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション 糖尿病の治療又は予防のためのジペプチジルペプチダーゼｉｖ阻害剤としてのアミノテトラヒドロピラン
US20080051387A1 (en) 2006-06-09 2008-02-28 Yuelian Xu Tetrahydropyrido[3,4-d]pyrimidines and related analogues
JP2009007273A (ja) 2007-06-27 2009-01-15 Ajinomoto Co Inc ジアミノピリミジン化合物の製造方法
JP6025243B2 (ja) 2012-05-10 2016-11-16 富士フイルム株式会社 光電変換素子及びそれを用いた撮像素子
JP6172355B2 (ja) 2016-07-21 2017-08-02 富士ゼロックス株式会社 送受信システム及びプログラム

Also Published As

Publication number Publication date
UY30229A1 (es) 2007-07-31
KR101461376B1 (ko) 2014-11-26
WO2007109355A2 (en) 2007-09-27
US9422293B2 (en) 2016-08-23
SI2024368T1 (sl) 2014-08-29
EA200802020A1 (ru) 2009-04-28
KR20090006098A (ko) 2009-01-14
US20070225275A1 (en) 2007-09-27
NZ571343A (en) 2011-09-30
BRPI0709034A2 (pt) 2011-06-21
RS53436B (en) 2014-12-31
AU2007227203B2 (en) 2013-01-10
JP5232768B2 (ja) 2013-07-10
UA92636C2 (en) 2010-11-25
EP2024368B1 (en) 2014-04-30
MX2008012163A (es) 2008-12-16
NO20084411L (no) 2008-11-03
US20140135311A1 (en) 2014-05-15
CN101448835B (zh) 2012-06-27
US20160318942A1 (en) 2016-11-03
EA017069B1 (ru) 2012-09-28
TW200813061A (en) 2008-03-16
WO2007109355A3 (en) 2007-11-15
HK1129888A1 (en) 2009-12-11
ZA200808975B (en) 2009-12-30
CN101448835A (zh) 2009-06-03
ECSP088807A (es) 2008-11-27
NO341676B1 (no) 2017-12-18
JP2009530396A (ja) 2009-08-27
EP2024368A2 (en) 2009-02-18
AU2007227203A1 (en) 2007-09-27
DK2024368T3 (da) 2014-05-19
ES2474152T3 (es) 2014-07-08
PL2024368T3 (pl) 2014-09-30
TWI440639B (zh) 2014-06-11
PT2024368E (pt) 2014-07-17
CA2646977C (en) 2015-08-25
CR10387A (es) 2009-02-23
CA2646977A1 (en) 2007-09-27
US8673895B2 (en) 2014-03-18
SG177176A1 (en) 2012-01-30
US9738649B2 (en) 2017-08-22
PE20080145A1 (es) 2008-02-11
BRPI0709034B1 (pt) 2022-05-31
NI200800253A (es) 2012-11-30
HRP20140664T1 (hr) 2014-10-10

Similar Documents

Publication Publication Date Title
AR059985A1 (es) Tetrahidro-pirimidoazepinas como moduladores de trpv1
AR061761A1 (es) Moduladores tiazolopirimidina de trpv1
AR089134A1 (es) Arilos y heteroarilos biciclicos inhibidores de los canales de sodio
AR069777A1 (es) Moduladores imidazolo-, oxazolo-, tiazolopirimidina del trpv1
HRP20160253T1 (hr) Inhibitor benzodiazepinske bromodomene
RU2013132683A (ru) Ингибиторы репликации вирусов гриппа
AR082891A1 (es) Di-azetidinil diamidas como inhibidores de monoacilglicerol lipasas
AR054863A1 (es) DERIVADOS DE 1H-PIRROLO[3, 4-C]PIRAZOL, UN PROCESO PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO O PROFILAXIS DE ENFERMEDADES ASOCIADAS CON EL FACTOR DE COAGULACIoN XA
AR065891A1 (es) Derivados de piridina y pirimidina como antagonistas del mglur2
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR065876A1 (es) Compuestos activos para 11 beta -hsd1
AR092045A1 (es) Combinaciones farmaceuticas
JP2015509927A5 (es)
EA201591775A1 (ru) Замещенные ароматические соединения и связанный с ними способ лечения фиброза
AR097008A1 (es) Derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR065464A1 (es) Derivados de nicotinamida. composiciones farmaceuticas
AR076024A1 (es) Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
AR057063A1 (es) Moduladores de tienopirimidina y tienopiridina quinasa y composicion farmaceutica
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
AR083180A1 (es) Amidas de oxopiperazina-azetidina y amidas oxodiazepina-azetidina como inhibidores de monoacilglicerol lipasa
AR093077A1 (es) ANTAGONISTAS DE mGlu2/3 PARA EL TRATAMIENTO DE LOS TRASTORNOS AUTISTAS
AR105965A1 (es) Derivados de piperidina puenteados
AR110122A1 (es) Fenoxitriazoles
AR109950A1 (es) INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
HRP20181027T1 (hr) Derivati fuzioniranog triazola kao inhibitori fosfodiesteraze 10a

Legal Events

Date Code Title Description
FG Grant, registration